BUSINESS● LOWSep 15 · Sep 15, 2026, 8:54 PM
Novartis' Lutathera now facing generic competition from Cirium's Bexlutry
Seeking Alpha Tech · global
Novartis' drug Lutathera is now facing generic competition from Cirium's Bexlutry, indicating a shift in the pharmaceutical market for this specific treatment. This could impact Novartis' market share and revenue.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS29m agoNaturgy Energy Group, S.A. reports Q3 resultsSeeking Alpha TechBUSINESS30m agoBorgWarner increases 2026 adjusted EPS guidance to $5.20-$5.35 while expecting $300M turbine generator revenue in 2027Seeking Alpha Tech